Moe Alsumidaie

http://Moe%20Alsumidaie
Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.

Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression

The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Raviv Pryluk from Phase V

  • By Moe Alsumidaie
  • October 3, 2024

Previous post
Mumbi Kairu on FDA’s Guidance on Diversity Inclusion in Clinical Trials
Next post
Interview with Bonne Adams of Inhibrx

Latest News

  • eClinical Solutions hosts ENGAGE 2026 with 250+ attendees from 75+ life science firms 01
    News

    eClinical Solutions hosts ENGAGE 2026 with 250+ attendees from 75+ life science firms

    October 13, 2026
  • WCG's Activation Intelligence Saves 20 Hours Per Study Activation 02
    News

    WCG’s Activation Intelligence Saves 20 Hours Per Study Activation

    October 13, 2026
  • GCCL and LabConnect Sign MOU for Cross-Regional Clinical Trial Support 03
    News

    GCCL and LabConnect Sign MOU for Cross-Regional Clinical Trial Support

    October 13, 2026
  • AKIR001 radiopharmaceutical shows no dose-limiting toxicities in eight patients 04
    News

    AKIR001 radiopharmaceutical shows no dose-limiting toxicities in eight patients

    October 13, 2026
  • ArkBio Gets FDA Clearance for AK0406 Influenza Prevention Phase II Trial 05
    News

    ArkBio Gets FDA Clearance for AK0406 Influenza Prevention Phase II Trial

    October 13, 2026
  • Sponsors Should Match Outsourcing Model to Development Strategy, Not Vice Versa 06
    News

    Sponsors Should Match Outsourcing Model to Development Strategy, Not Vice Versa

    October 12, 2026
The Clinical Trial Vanguard
  • ABOUT US
  • Log In
  • Membership Account
    • Membership Billing
    • Membership Cancel
    • Membership Orders
    • Your Profile
  • Membership Checkout
    • Membership Confirmation
  • Membership Levels
  • PRIVACY POLICY
  • SUBSCRIBE
  • TERMS AND CONDITIONS OF ACCESS AND USE
Copyright © 2026 The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Start typing and press Enter to search

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}